{"id":"W4390640719","doi":"10.1016/j.eururo.2023.12.004","title":"Safety Analyses of the Phase 3 VISION Trial of [177Lu]Lu-PSMA-617 in Patients with Metastatic Castration-resistant Prostate Cancer","year":2024,"lang":"en","type":"article","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; Medical Research Council; Advanced Accelerator Applications; Novartis; Endocyte; Genentech; Novartis Pharmaceuticals Corporation; Pfizer; Amgen","keywords":"Medicine; Prostate cancer; Oncology; Castration; Internal medicine; Prostate; Urology; Cancer; Hormone","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00482289,0.0009734687,0.001913001,0.0003540372,0.0003157474,0.001059273,0.0007212654,0.0009055152,0.002088835],"category_scores_gemma":[0.004436343,0.000478451,0.002851482,0.0004505271,0.0008084648,0.0006325871,0.0003356452,0.002214447,0.0003175015],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009515614,"about_ca_system_score_gemma":0.001456148,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005131637,"about_ca_topic_score_gemma":0.001202296,"domain_scores_codex":[0.9973073,0.002051221,0.00009387042,0.0001989635,0.0001994189,0.0001492647],"domain_scores_gemma":[0.9977064,0.0008250276,0.0007315358,0.0002178887,0.0001778159,0.0003412964],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9236245,0.007046746,0.004215624,0.0009680838,0.003981569,0.0001274408,0.0001570497,0.003299773,0.01307401,0.0003682797,0.001841583,0.04129519],"study_design_scores_gemma":[0.5234498,0.4355893,0.02381894,0.00008438962,0.003854087,0.0003321795,0.0000868129,0.003480485,0.004745335,0.0009645799,0.003516402,0.00007767222],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.992703,0.002931042,0.0008221946,0.0002107818,0.00009069002,0.0009820041,0.0007223537,0.00006175989,0.001476306],"genre_scores_gemma":[0.9948754,0.001027487,0.0007115099,0.0003644767,0.0001356804,0.001015906,0.0009859437,0.00003590617,0.0008477279],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00482289,"threshold_uncertainty_score":0.0255062,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04212275365310404,"score_gpt":0.3882628195143704,"score_spread":0.3461400658612663,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}